Prioritizing vaccines for developing world diseases

Research output: Contribution to journalComment/debate

Abstract

A major disparity in the burden of health will need to be addressed to achieve the “Grand Convergence” by 2035. In particular people living in low and middle income countries have a much higher burden of infectious diseases. Although vaccines have been very effective in reducing the global burden of infectious disease, there are no registered vaccines to address 60% of the current burden of infectious disease, especially in developing countries. Thus there is a pressing need for new vaccines and for prioritizing vaccine development given that resources for developing new vaccines are strictly limited. As part of the GLOBAL HEALTH 2035: Mission Grand Convergence meeting one working group assessed the SMART vaccine algorithm as a mechanism for prioritizing vaccine development for diseases of priority in the developing world. In particular, the working group considered which criteria in the standard SMART set were considered “key” criteria and whether other criteria should be considered, when prioritizing vaccines for this important set of countries.

Original languageEnglish (US)
Pages (from-to)A16-A19
JournalVaccine
Volume35
DOIs
StatePublished - Jan 20 2017

Fingerprint

Vaccines
vaccines
infectious diseases
vaccine development
Communicable Diseases
developing countries
income
Developing Countries
Health

Keywords

  • Developing world
  • Neglected diseases
  • Prioritization
  • Strategic Multi-Attribute Ranking Tool
  • Vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Prioritizing vaccines for developing world diseases. / Saul, Allan; O'Brien, Katherine L.

In: Vaccine, Vol. 35, 20.01.2017, p. A16-A19.

Research output: Contribution to journalComment/debate

@article{5bbe514dc95245879dc0b2827723886d,
title = "Prioritizing vaccines for developing world diseases",
abstract = "A major disparity in the burden of health will need to be addressed to achieve the “Grand Convergence” by 2035. In particular people living in low and middle income countries have a much higher burden of infectious diseases. Although vaccines have been very effective in reducing the global burden of infectious disease, there are no registered vaccines to address 60{\%} of the current burden of infectious disease, especially in developing countries. Thus there is a pressing need for new vaccines and for prioritizing vaccine development given that resources for developing new vaccines are strictly limited. As part of the GLOBAL HEALTH 2035: Mission Grand Convergence meeting one working group assessed the SMART vaccine algorithm as a mechanism for prioritizing vaccine development for diseases of priority in the developing world. In particular, the working group considered which criteria in the standard SMART set were considered “key” criteria and whether other criteria should be considered, when prioritizing vaccines for this important set of countries.",
keywords = "Developing world, Neglected diseases, Prioritization, Strategic Multi-Attribute Ranking Tool, Vaccines",
author = "Allan Saul and O'Brien, {Katherine L}",
year = "2017",
month = "1",
day = "20",
doi = "10.1016/j.vaccine.2016.10.087",
language = "English (US)",
volume = "35",
pages = "A16--A19",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Prioritizing vaccines for developing world diseases

AU - Saul, Allan

AU - O'Brien, Katherine L

PY - 2017/1/20

Y1 - 2017/1/20

N2 - A major disparity in the burden of health will need to be addressed to achieve the “Grand Convergence” by 2035. In particular people living in low and middle income countries have a much higher burden of infectious diseases. Although vaccines have been very effective in reducing the global burden of infectious disease, there are no registered vaccines to address 60% of the current burden of infectious disease, especially in developing countries. Thus there is a pressing need for new vaccines and for prioritizing vaccine development given that resources for developing new vaccines are strictly limited. As part of the GLOBAL HEALTH 2035: Mission Grand Convergence meeting one working group assessed the SMART vaccine algorithm as a mechanism for prioritizing vaccine development for diseases of priority in the developing world. In particular, the working group considered which criteria in the standard SMART set were considered “key” criteria and whether other criteria should be considered, when prioritizing vaccines for this important set of countries.

AB - A major disparity in the burden of health will need to be addressed to achieve the “Grand Convergence” by 2035. In particular people living in low and middle income countries have a much higher burden of infectious diseases. Although vaccines have been very effective in reducing the global burden of infectious disease, there are no registered vaccines to address 60% of the current burden of infectious disease, especially in developing countries. Thus there is a pressing need for new vaccines and for prioritizing vaccine development given that resources for developing new vaccines are strictly limited. As part of the GLOBAL HEALTH 2035: Mission Grand Convergence meeting one working group assessed the SMART vaccine algorithm as a mechanism for prioritizing vaccine development for diseases of priority in the developing world. In particular, the working group considered which criteria in the standard SMART set were considered “key” criteria and whether other criteria should be considered, when prioritizing vaccines for this important set of countries.

KW - Developing world

KW - Neglected diseases

KW - Prioritization

KW - Strategic Multi-Attribute Ranking Tool

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85009247649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009247649&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2016.10.087

DO - 10.1016/j.vaccine.2016.10.087

M3 - Comment/debate

C2 - 28017442

AN - SCOPUS:85009247649

VL - 35

SP - A16-A19

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -